<DOC>
	<DOCNO>NCT00305474</DOCNO>
	<brief_summary>This study seek determine whether adult , non-psychotic , first-degree relative schizophrenic patient show specific neurocognitive deficit negative symptom show improvement area follow 6-month , double-blind trial low dose ( 2.0 mg ) risperidone .</brief_summary>
	<brief_title>Identification Treatment Liability Develop Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Having least one firstdegree biological relative schizophrenia age 19 59 . Desire participate medication trial . Is able provide inform consent . Having moderate level negative symptom , define 6 item rat 3 high Scale Assessment Negative Symptoms ( SANS ) . Scoring two standard deviation normal least one three cognitive domain : vigilance/working memory , longterm verbal memory , executive function . Scoring least one standard deviation normal second cognitive domain . IQ le 80 . Formal education le 10 year . History psychotic disorder . History treatment antipsychotic medication . A substance abuse diagnosis within 6 month diagnosis . A head injury document loss consciousness exceed 5 minute ( subsequent cognitive deficit ) . A history neurologic disease damage . A medical condition significant cognitive sequela . A history electroconvulsive treatment .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Negative symptom</keyword>
	<keyword>neuropsychological deficit</keyword>
	<keyword>Cognitive function</keyword>
	<keyword>diagnostic</keyword>
	<keyword>prevention</keyword>
</DOC>